Gene
EPHA3
EPHA3 is a gene biomarker in the evidence tier "Cancer actionable (CGI)". This page lists evidence by type: Assay-provider ledger (2), Actionable biomarkers (1), Trial mentions (6), and 7 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
2 more sections with rows · 2 sections measured, none recorded
Cancer actionable (CGI)
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention EPHA3. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers. Not plotted: 1 with no date at all.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers. Not plotted: 2 at the structurally incomplete recent edge.
EPHA3 has 5 trial mentions across 5 years. That is too few to read as a trend, so the years are listed instead.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 0 of 8,738 | 0.00% | not measured | |
| 2025 | 0 of 8,875 | 0.00% | not measured | |
| 2024 | 0 of 8,597 | 0.00% | not measured | |
| 2023 | 0 of 8,275 | 0.00% | 4 of 11,460 | 0.03% |
| 2022 | 0 of 8,285 | 0.00% | 2 of 13,598 | 0.01% |
| 2021 | 0 of 8,692 | 0.00% | 1 of 15,045 | 0.01% |
| 2020 | 1 of 7,640 | 0.01% | 5 of 14,459 | 0.03% |
| 2019 | 1 of 7,300 | 0.01% | 3 of 12,159 | 0.02% |
| 2018 | 1 of 6,927 | 0.01% | 3 of 11,854 | 0.03% |
| 2017 | 0 of 6,558 | 0.00% | 3 of 11,595 | 0.03% |
Showing 10 of 37 years.
Assay-provider ledger (2)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| Dxome Co. Ltd. | Diagnostic provider | Clinical validationAnalytical validation | 1 | March 01, 2026 |
| Foundation Medicine | Diagnostic provider | No clinical or analytical validation recorded for this pair | 1 | September 01, 2014 |
Actionable biomarkers (1)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| EPHA3 amplification | Epha3 Inhibitors | response-associated | No disease recorded | Cancer Genome Interpreter |
Trial mentions (6)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT01218659 | Trial eligibility (AACT) |
| NCT01476163 | Trial eligibility (AACT) |
| NCT01888627 | Trial eligibility (AACT) |
| NCT03837184 | Trial eligibility (AACT) |
| NCT03459664 | Trial eligibility (AACT) |
Showing 5 of 6 trial mentions.
Target-disease associations (542)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| ATTRV122I amyloidosis | cardiovascular disease | Mouse knockout (IMPC) |
| Abruptio Placentae | pregnancy or perinatal disease | GWAS credible sets |
| Ampulla of Vater Carcinoma | cancer or benign tumor | Cancer Gene Census |
| Anaplastic (Malignant) Meningioma | cancer or benign tumor | Cancer Gene Census |
| Aortic Coarctation | cardiovascular disease | Mouse knockout (IMPC) |
Showing 5 of 542 associations.
Vendor sourcing (60)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| AOK Rheinland/Hamburg | Trial collaborator | Named in trial inclusion criteriaTrial eligibility criteria | : * Age ≥16 years * insured in one of the relevant health insurances (BARMER GEK, AOK Rheinland/Hamburg, DAK Gesundheit, HEK, BKK Linde, BKK Mobil Oil, BKK ... | View trial NCT03459664 |
| AOK Rheinland/Hamburg | Trial collaborator | Mentioned in trial textTrial free-text mention | HEK | View trial NCT03459664 |
| Ambry Genetics (United States) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The c.2051G>A (p.R684Q) alteration is located in exon 11 (coding exon 11) of the EPHA3 gene. This alteration results from a G to A substitution at nucleotide... | View ClinVar record SCV003551096.3 |
| Amicus Therapeutics (United States) | Trial sponsor | Named in trial inclusion criteriaTrial eligibility criteria | : * Confirmed GLA mutation predicted to be responsive migalastat in the human embryonic kidney (HEK-293) cell-based assay * At least 2 years of age * Strong... | View trial NCT01476163 |
| Amicus Therapeutics (United States) | Trial sponsor | Named in trial inclusion criteriaTrial eligibility criteria | : * Male or female between the ages of 16 and 74 diagnosed with Fabry disease * Confirmed α Gal-A mutation that is amenable to migalastat, based on the clin... | View trial NCT01218659 |
Showing 5 of 60 sourcing records.
Trial-cited literature (35)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| Feasibility and acceptability of phone-delivered psychological therapy for refugee children and adolescents in a humanitarian setting. | Conflict and health | 2024 | 5 |
| A participatory research to assess how a student citizens' assembly can facilitate the co-creation of nutrition interventions in higher education settings. | BMC public health | 2024 | 1 |
| Venetoclax and idasanutlin in relapsed/refractory AML: a nonrandomized, open-label phase 1b trial. | Blood | 2023 | 87 |
| Comprehensive analyses of immune tumor microenvironment in papillary renal cell carcinoma. | Journal for immunotherapy of cancer | 2023 | 14 |
| Pucotenlimab in patients with advanced mismatch repair-deficient or microsatellite instability-high solid tumors: A multicenter phase 2 study. | Cell reports. Medicine | 2023 | 8 |
Showing 5 of 35 papers.
Protein variant mentions (2)
Shown in this order: alphabetical by variant.
| Variant | Distinct papers | Year range | Sample papers |
|---|---|---|---|
| p.G114X | 1 | 2019 | PMID 30862609 |
| p.M320I | 1 | 2012 | PMID 22980976 |
Human sample screening reference (1)
Shown in this order: alphabetical by variant.
| Variant | GDC project | Disease / site | Affected cases | Profiled cases | Observed frequency | 95% interval |
|---|---|---|---|---|---|---|
| p.M320I | TCGA-BRCA | Cystic, Mucinous and Serous Neoplasms; Adenomas and Adenocarcinomas; Fibroepithelial Neoplasms; Basal Cell Neoplasms; Ductal and Lobular Neoplasms; Epithelial Neoplasms, NOS; Squamous Cell Neoplasms; Complex Epithelial Neoplasms; Adnexal and Skin Appendage Neoplasms; Breast | 1 | 1,098 | 0.09% | 0.02% to 0.51% |
Literature-extracted relations (4)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| Hematologic Neoplasms | Disease | associate |
KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study. | 2016 |
| Small Cell Lung Carcinoma | Disease | associate |
Next-generation sequencing reveals frequent consistent genomic alterations in small cell undifferentiated lung cancer. | 2014 |
| Adenocarcinoma of Lung | Disease | associate |
Somatic mutations affect key pathways in lung adenocarcinoma. | 2008 |
| Neoplasms | Disease | associate |
Somatic mutations affect key pathways in lung adenocarcinoma. | 2008 |
Organizations publishing (171)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| The University of Texas System | Academic | 3 | 2016 to 2023 |
| University of California System | Academic | 3 | 2014 to 2023 |
| Institut Paoli-Calmettes | Nonprofit | 2 | 2023 |
| Mayo Clinic | Hospital | 2 | 2018 to 2019 |
| Moffitt Cancer Center | Hospital | 2 | 2016 |
Showing 5 of 171 organizations.
Where EPHA3 appears
- biological_process
- cancer or benign tumor
- cardiovascular disease
- endocrine system disease
- gastrointestinal disease
- genetic, familial or congenital disease
- immune system disease
- injury, poisoning or other complication
- measurement
- medical procedure
- nervous system disease
- nutritional or metabolic disease
- phenotype
- pregnancy or perinatal disease
- reproductive system or breast disease
- respiratory or thoracic disease
496 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions and fda biomarker qualification projects.